Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

KW-2449 safe and well tolerated in phase I study in hematologic malignancies

Dec. 14, 2007

Zevalin meets primary endpoint in follicular non-Hodgkin's lymphoma trial

Dec. 14, 2007

FDA grants approval to SKCC for phase I clinical trial of breast cancer vaccine

Dec. 13, 2007

Celsion refiles for an FDA Special Protocol Assessment for phase III trial of ThermoDox

Dec. 13, 2007

BioInvent designates BI-505 for blood cancer as new drug candidate

Dec. 13, 2007

BioCancell reports successful experimental treatment using BC-819 for ovarian cancer

Dec. 13, 2007

Bv8 promotes tumor growth through angiogenesis

Dec. 13, 2007

Carfilzomib well tolerated in consecutive-day schedule in hematologic malignancies

Dec. 13, 2007

SymBio initiates phase II clinical study of bendamustine hydrochloride

Dec. 12, 2007

Serenex initiates phase I trial of SNX-5422 for hematological malignancies

Dec. 12, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...